Clinical Trial Search

Primary: Overall Survival — 17.5; 14.2; 18.1; 14.2 Months — p=0.0565

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 100.0; 100.0; 100.0 percentage of participants

Primary: Diastolic Blood Pressure Change — -8.56; -11.26 mmHg — p=0.0001

Primary: Percentage of Subjects With Seroprotective Immune Response — 95.1; 81.3 Percentage of Participants

Primary: Time to 10%, 50%, 90% and Complete Gastric Empting of the Radioactive Markers Representing Sumatriptan, Naproxen and Eletriptan — 0.100; 0.130; 1.195; 1.300 hours (hr)

Primary: Standardized Baseline-adjusted Trough Morning Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks…

Primary: Antepartum Component: Number of Confirmed Infant HIV Infections — 25; 7; 2 Participants

Primary: Co-primary Efficacy Variables: Percent Positive and Percent Negative Agreement of Macimorelin-GHST (MAC) With ITT — 55; 4; 19; 62 Participants

Primary: Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)…

Primary: Change in Cognition — 0.68; 0.13 units on a scale — p=0.2365

Primary: Change From Baseline in the Unified Dyskinesia Rating Scale (UDysRS) Score at Week 12 — -8.0; -15.9 units on a scale — p=0.0009

Primary: Changes in Serum 25(OH)D3 Levels — 11; 22; 7.5; 25 ng/mL

Primary: Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue — -3.007; -2.123; -2.794 % HbA1c — p=<0.001

Primary: Change in Peak Serum IL-6 Concentration — 11.5; 29.3 pg/ml — p=<0.001

Primary: Percentage of Participants Achieving American College of Rheumatology (ACR) 20 Response at Week 16 — 24.1; 40.1; 45.2 Percentage of Participants — p=< 0.001